INTRODUCTION
Opioid receptors mediate the various functions of opioids and endogenous opioid peptides, including analgesia, euphoria, respiratory depression, and endocrine/immune regulation. Opioid receptors have been classified into three major types ( , , and ) using pharmacological studies and subsequently by molecular cloning studies (1) . They are mainly expressed in the central nervous system (CNS) (2, 3) and peripheral tissues such as immune cells (4) (5) (6) . All three types of receptors belong to the superfamily of Gprotein-coupled receptors (2) , and the opioid receptor (MOR) is known to play an essential role in morphine-induced analgesia, tolerance, and dependence as indicated from pharmacological studies, i.e.,
MOR gene knock-out studies (7).
The MOR is expressed mainly in the CNS, where it exhibits distinct temporal and spatial patterns of distribution (1) . MOR is also detected in immune cells, such as rat peritoneal macrophages (8) , and a variety of human and monkey immune cells, including human CEM x174 T/B lymphocytes, human Raji B cells, human CD+ cells, human monocytes/macrophages, human neutrophils, monkey peripheral blood mononuclear cells (PBMC), and monkey neutrophils (4) . The existence of MOR in immune cells can explain why drug abusers (opioids and heroin) frequently become more susceptible to external pathogenic 6 luciferase and galactosidase activities of each lysate were determined as described by the manufacturers (Promega and Tropix, respectively). For co-transfection assays, the procedures were the same as above, except that the plasmids were a mixture of the given amount of PU.1 construct and 0.5 g of a corresponding reporter plasmid, pL1.3K/687, pL1.3K/728, Linker 3, Linker 6, and Linker 7.
For Trichostatin A (TSA, Sigma) and 5-Aza-2'-deoxycytidine (5-Aza-dC, Sigma) treatments, the pL1.3K/687 plasmid was transiently co-transfected either with vector pJ6 or with PU.1 plasmid into NMB cells, and 24 hrs after the co-transfection the cells were treated with indicated amounts of either TSA or 5-Aza-dC. Luciferase activities were analyzed after 24 hrs treatment.
Yeast One-Hybrid Screening for cDNAs Encoding Negative Regulatory DNA-binding Proteins-
The MATCHMAKER One-Hybrid System (Clontech) was used according to the supplier's protocol. The following yeast one-hybrid screening was carried out as described in our recent paper (29) Plasmids from five positive blue clones were sequenced, and their homology was analyzed using the BLAST algorithm.
Electrophoretic Mobility Shift Assay (EMSA) and Supershift Assay-Nuclear extracts from mouse brain and RAW264.7 cells were prepared using a modification of Dignam's procedure (30, 31) . The upper and lower strands of each probe were annealed and the double-stranded oligonucleotides were then endlabeled with [ -32 P] ATP. The end-labeled DNA probes were incubated with nuclear extracts or 2 l of in vitro translated products in a final volume of 20 l EMSA buffer (10 mM Tris·HCl, pH 7.5, 5 % glycerol, 50
mM NaCl, 1 mM dithiothreitol, 1 mM EDTA, and 0.1 mg/ml poly (dI-dC)) at room temperature for 30 min.
For oligonucleotide competition analysis, a 100 fold molar excess of cold competitor oligonucleotide was added to the mixture prior to adding the probe. For supershift assay, samples were incubated with 1 l of each antibody for 30 min before adding the probe. The reaction mixtures were electrophoresed in 4 % polyacrylamide nondenaturing gel in 0.5x TBE buffer (45 mM Tris-borate and 1 mM EDTA) at 4 °C and visualized by autoradiography. Polyclonal anti-FLAG antibody was purchased from Sigma. Anti-NRSF (neuron-restrictive silencer factor), anti-PU.1 (T-21, C-terminal epitope), and anti-PU.1 (D-19, N-terminal epitope) antibodies were obtained from Santa Cruz Biotech. Anti-HDAC1 antibody was purchased from GeneTax, Inc.
Chromatin Immunoprecipitation Assay (ChIP)-RAW264.7 and C6 cells were used for ChIP assays.
ChIPs were performed by using a modified protocol from Upstate Biotechnology (Lake Placid, NY). Cells in a 10-cm dish (70 % confluent) were treated for 10 min with 1 % formaldehyde at room temperature. The cells were lysed in cell lysis buffer (5 mM Hepes, pH 8.1, 85 mM KCl, 0.5 % Triton X-100), and the nuclei were resuspended in nuclei lysis buffer (50 mM Tris·HCl, pH 8.1, 10 mM EDTA, 1 % SDS forward, 5'-GCTTCTTTCACAAAAATTT-3' and D7AS reverse, 5'-CCATATCTGAGGGAAAAC-3'. For rat MOR primers, the above same D2S and rD8AS (produce 208-bp PCR DNA size); rD8AS reverse, 5'-ATACTTAAACACTCTTCCGACTCA-3' were used. After 35 cycles of amplification, 8 µl of PCR product was analyzed on a 1.5 % agarose gel.
PU.1 Knock-out Mice and RT-PCR Experiments-
The generation of PU.1 null mice has been reported previously (32) . The mice brain samples were obtained from the mid-and hindbrain of the animals.
The brains were homogenized in one ml of RNA-Bee (TEL-TEST Inc.) with a Dounce homogenizer. All samples were placed immediately on dry ice and stored at -80 °C until used. Total RNA was isolated according to the supplier's protocol (TEL-TEST Inc. gene are underlined and the remaining 3'-regions of each primer are the corresponding T7 promoter sequences. T7 si primer, 5'-GGATCCTAATACGACTCACTATAG-3' was synthesized and scrambled primers (sense and antisense) as negative siRNA control were also synthesized. The oligonucleotidedirected production of small RNA transcripts with T7 RNA polymerase, previously described (35) (34), was carried out using T7 RiboMAX Express RNAi system (Promega). Sense and antisense 21-nt RNAs generated in separate reactions were annealed by mixing both transcription reactions, incubating at 70 °C for 10 min followed by 20 min at room temperature to obtain small interfering double-stranded RNA synthesized by T7 RNA polymerase. The mixture was then purified by isopropanol precipitation, followed by 70 % ethanol washing, dried, and resuspended in appropriate amount of nuclease-free water.
The concentration of siRNAs was optimized to 2.5 g in each transfection for RAW264.7 cells using RNAiFect transfection reagent (Qiagen). Forty eight hrs after the transfection, total RNA and protein samples were prepared using TRI Reagent (Molecular Research Center, Inc. (25) . To determine whether this negative cis-acting element could recruit transcriptional factors to regulate the promoter activity, EMSA experiments were carried out using nuclear extracts from mouse brain. A double-stranded oligonucleotide, SL-1 ( Fig. 2A) was prepared spanning the region from -731 to -681 of the MOR promoter covering the region of 34-bp cis-acting element (-721 to -687) with the flanking sequences on both ends. The SL-1 sequence, containing the negative cis-acting element, could form sequence specific DNA-protein complexes with the nuclear extracts of mouse brain (data not shown), suggesting the presence of endogenous transcription factors in brain.
RESULTS

Isolation of Transcription Factors that
To identify transcription factors that bind to the negative element of the distal promoter, we utilized the yeast one-hybrid system to screen an adult mouse brain GAL4-AD fusion cDNA library ( Fig. 1A and B).
The following yeast one-hybrid procedures are very similar to what we had done in our previous paper (29) , with minor modifications as described below. The SL-1 sequence ( Fig. 2A ) was used as bait, because it contains additional flanking sequences along with the 34-bp cis-acting element that could be important for transcription factor-binding affinity. A double-stranded oligonucleotide having four tandem repeats of the SL-1 sequence was subcloned into pHISi. The resulting plasmid pHISi-4xNM was integrated into the yeast YM4271 genome. Using this yeast strain, 6x10 6 independent colonies from the library were screened. A total of five independent clones (histidine-positive clones) were selected ( Fig. 1A and B ) and sequenced.
The results revealed that one of the clones is identical to a PU.1 transcription factor. Some of the other positive (His+ and LacZ+) clones have been identified as COUP-TFII (36); NGFI-B (37); TR2-11 (38) . The potential regulatory role of these factors in the MOR gene transcription is currently under investigation in our laboratory.
To exclude the possibility that this SL-1 element may form some specific sequences with the minimal HIS3 promoter that favor binding of the PU.1 protein, we used another reporter (LacZ) yeast strain containing pLacZi-4xNM construct. We also used a control yeast strain without repeats of the cis-acting The ability of PU.1 cDNA to encode proteins was verified by in vitro translation, and the products were analyzed on SDS-PAGE. The in vitro translated PU.1 protein was electrophoresed and found to be the correct size as expected from the calculated molecular weights (data not shown). To confirm whether the isolated PU.1 protein can indeed bind to the negative cis-acting element, EMSAs were carried out using in vitro translated PU.1 protein product. The PU.1 protein was able to shift the target SL-1 oligonucleotide probe ( Fig. 1C , Lane 1). The specificity of this DNA-protein interaction was verified by competitive inhibition in the presence of cold self-competitor using the PU.1 protein (Fig. 1C , Lane 4), while the mutated PU.1 competitor was not able to block the complex (data not shown). To further confirm the specificity of PU.1-DNA interaction, we performed supershift assay using in vitro translated FLAG-tagged 12 serum, indicating the specificity of the interaction between the FLAG antibody and the complex. We conclude that the in vitro translated PU.1 protein has affinity for and binds to the PU.1-binding motif within the probe SL-1. by supershift assay using PU.1-specific antibodies (Fig. 2C ). Competition either with a SL-mPU oligonucleotide or an mPU.1 oligonucleotide, which were both mutated at the PU.1 sites, had no effect on the major band (Lanes 4 and 6 of Fig. 2B , respectively). Competition either with the self-competitor or the PU.1 consensus competitor (39) was able to abolish the major band (Lanes 3 and 5 of Fig. 2B , respectively),
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indicating that the PU.1 protein interacts with the cis-acting element in a sequence-specific manner. To further confirm the PU.1 interactions, a supershift assay was carried out. Two separate PU.1 antibodies, 13 but the major band was not supershifted with either preimmune serum as a negative control or NRSF (neuron-restrictive silencer factor) antibody as a non-specific antibody control (Fig. 2C) , indicating that the major band consists of a complex between PU.1 protein from the immune cells RAW264.7 and the cisacting element. These results demonstrate that PU.1 binds to the mouse MOR promoter, and it is possible that this factor may play a role in the regulation of MOR promoter activity in immune cells. In addition, methylation inhibitor, 5-Aza-2'-deoxycytidine (5-Aza-dC), was used. It was reported that direct association between PU.1 and MeCP2, a methyl CpG binding protein, could recruited mSin3A-HDAC complex for PU.1-mediated transcriptional repression in murine erythroleukemia (MEL) cells (54) .
PU.1 Protein Regulates MOR
In that study, the MeCP2 repressed PU.1-mediated activation of transcriptional activity containing PU.1 binding sites and this down-regulation was recovered in the presence of histone deacetylase inhibitor, Trichostatin A (TSA). However, in our study, the treatment with 5-Aza-dC as a methylation inhibitor did not influence MOR promoter activities of both vector control and PU.1 co-transfection (Fig. 4B ). This result suggests that MeCP2, previously known to act as a co-repressor of PU.1, does not facilitate complex Small interfering RNA-based (siRNA) strategy (34) was employed to silence the endogenous PU.1 expression in RAW264.7 cells, since there may be complicating factors in gene knock-out mice studies, making it difficult to assign a direct role for a target gene. PU.1 and scrambled siRNAs were generated according to Donze's procedure (34) and the T7 RiboMAX Express RNAi system (Promega). The concentration of siRNAs was optimized to 2.5 g in each transfection for RAW264.7 cells. In Fig. 6A , transfection of PU.1 siRNA resulted in a complete silencing of the PU.1 gene at the protein level.
Transfection of scrambled siRNA as a non-specific sequence control had no effect on PU.1 expression compared to the no siRNA transfection control, indicating high efficiency of the siRNA strategy. Expression of the target MOR was dramatically increased with PU.1 siRNA transfection both at the protein and mRNA levels ( Fig. 6A and B, respectively), compared to scrambled siRNA and no transfection, showing in vivo evidence of the PU.1 function on endogenous MOR gene regulation. Fig. 6C is a quantitative analysis of two independent RT-PCR experiments measuring changes in MOR mRNA levels. Data was normalized to -actin and the graph was generated by using ImageQuant 5.2 (Amersham) software. LUC and DP represent luciferase reporter gene and MOR distal promoter, respectively. Transfection efficiencies were normalized as described above. The activities of the luciferase reporter were expressed as n-fold relative to the activity of each corresponding luciferase reporter with vector alone transfected, which was assigned an activity value of 1.0. 
DISCUSSION
